| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7923564 | ACADIA PHARMS INC | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Sep, 2025
(1 year, 11 months from now) | |
| US7732615 | ACADIA PHARMS INC | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Jun, 2028
(4 years from now) | |
| US7601740 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Apr, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9765053 | ACADIA PHARMS INC | Methods of treatment using selective 5-HT2A inverse agonists |
Jul, 2022
(1 year, 2 months ago) | |
| US10028944 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(3 months from now) | |
| US9566271 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(3 months from now) | |
| US8618130 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(3 months from now) | |
| US8921393 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(3 months from now) | |
| US7659285 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Aug, 2026
(2 years from now) | |
| US10953000 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(13 years from now) | |
| US10517860 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(13 years from now) | |
| US11452721 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(14 years from now) | |
| US10849891 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(14 years from now) | |
| US10449185 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(14 years from now) | |
| US10646480 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(14 years from now) | |
Nuplazid is owned by Acadia Pharms Inc.
Nuplazid contains Pimavanserin Tartrate.
Nuplazid has a total of 15 drug patents out of which 1 drug patent has expired.
Expired drug patents of Nuplazid are:
- US9765053
Nuplazid was authorised for market use on 29 April, 2016.
Nuplazid is available in tablet;oral dosage forms.
Nuplazid can be used as treatment of parkinson's disease psychosis, treatment of psychosis or a symptom thereof, treatment of a neurodegenerative disease or a symptom thereof, treatment of hallucinations and delusions associated with parkinson's disease psychosis.
The generics of Nuplazid are possible to be released after 27 August, 2038.
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
Market Authorisation Date: 29 April, 2016
Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of psychosis or a symptom thereof; Treatment of a neurodegenerative disease or a symptom thereof; Tre...
Dosage: TABLET;ORAL
NUPLAZID family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic